uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

uniQure N.V. (QURE)

We couldn't retrieve the full text for this release. Read it on the company's site.